Tag Archives: Adaptimmune

Adaptimmune’s ADP-A2M4CD8 Has a Best Response With Ovarian Cancer Patients; Legend’s LB1901 Ph1 Trial Initiated in the US

On Monday, September 13, Adaptimmune reported (press release / presentation) updated data from ADP-A2M4CD8’s (MAGE-A4 SPEAR-T) Ph1 SURPASS study for multiple solid tumors. Of note, Adaptimmune highlighted ADP-A2M4CD8’s safety profile and compared initial efficacy data to the company’s first-generation MAGE-A4 SPEAR-T therapy (afami-cel; formerly ADP-A2M4). On the same day, Legend announced (press release) the start of LB1901’s (CD4 CAR-T) Ph1 trial in the US for r/r peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Below, Celltelligence provides insights on which indications Adaptimmune could prioritize, while discussing Legend’s clinical development of LB1901 in the TCL setting.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune’s Novel Gene Editing Approach; Do iPSC-derived αβT Cells Have an Advantage Over NK Cells? Thoughts on Adaptimmune’s Allogeneic Platform Virtual Event 2021

On Thursday, September 9, Adaptimmune held a virtual event (presentation) discussing the scope of their recent Genentech (Roche) collaboration. Additionally, management highlighted Adaptimmune’s strategy to knockout recombination-activating gene (RAG) in order to eliminate native TCR expression, while announcing the completion of a new allogeneic manufacturing facility by YE 2022 in Milton Park, UK. Below, Celltelligence provides insights on how Adaptimmune’s collaboration with Genentech (Roche) could potentially impact GSK’s TCR-T strategy, Adaptimmune’s decision to develop iPSC-derived αβT cells, and which alternative lymphodepletion regimens could be used for their allogeneic products.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune Discusses Novel Engineering and Lymphodepleting Regimens During Their Allogeneic Platform Virtual Event 2021

On Thursday, September 9, Adaptimmune held a virtual event discussing their allogeneic platform (presentation). Although no significant updates were provided relating to the Genentech partnership, management discussed the overall scope and financial terms of the deal over two slides (see below).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune Partners With Genentech to Develop iPSC-derived Allogeneic TCR-Ts

On Tuesday, September 7, Adaptimmune announced (press release) a strategic collaboration and license agreement with Genentech (Roche) to develop and commercialize allogeneic T cell therapies for multiple oncology indications. Of note, Adaptimmune will receive $150M upfront and further milestone payments potentially exceeding $3B in aggregate value. Below, Celltelligence provides insights on how Genentech (Roche) could leverage their extensive capabilities to quickly advance allogeneic TCR-Ts into the clinic, while discussing Adaptimmune’s strategy to become a leader in the allogeneic TCR-T space.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK and Adaptimmune Present TCR-T Data for Lete-cel and Afami-cel; Novel CAR-Ts for Solid Tumors From Minerva and OriginCell; Will Remodeling the TME With CAR-Ts Improve Solid Tumor Therapies? ASCO 2021 Day 3 Part I

On the third day of ASCO 2021, seven key solid tumor related updates were presented from GSK, Adaptimmune, Minerva, OriginCell Therapeutics, Baylor College / NCI, and UPenn. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.